DK1589976T3 - Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose - Google Patents

Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose

Info

Publication number
DK1589976T3
DK1589976T3 DK04707574T DK04707574T DK1589976T3 DK 1589976 T3 DK1589976 T3 DK 1589976T3 DK 04707574 T DK04707574 T DK 04707574T DK 04707574 T DK04707574 T DK 04707574T DK 1589976 T3 DK1589976 T3 DK 1589976T3
Authority
DK
Denmark
Prior art keywords
progestin
endometriosis
estrogen
treatment
combination
Prior art date
Application number
DK04707574T
Other languages
Danish (da)
English (en)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1589976T3 publication Critical patent/DK1589976T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04707574T 2003-02-05 2004-02-03 Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose DK1589976T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
DK1589976T3 true DK1589976T3 (da) 2007-12-27

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04707574T DK1589976T3 (da) 2003-02-05 2004-02-03 Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose

Country Status (30)

Country Link
US (2) US7910570B2 (uk)
EP (2) EP1857111A3 (uk)
JP (2) JP4658918B2 (uk)
KR (1) KR101075929B1 (uk)
CN (1) CN100393360C (uk)
AR (1) AR043013A1 (uk)
AT (1) ATE374612T1 (uk)
AU (1) AU2004210184B2 (uk)
BR (1) BRPI0407039A (uk)
CA (1) CA2513910C (uk)
CO (1) CO5580789A2 (uk)
CY (1) CY1107816T1 (uk)
DE (1) DE602004009288T2 (uk)
DK (1) DK1589976T3 (uk)
ES (1) ES2293215T3 (uk)
GB (1) GB0302572D0 (uk)
HK (1) HK1082918A1 (uk)
IL (1) IL169583A0 (uk)
IS (1) IS2547B (uk)
MX (1) MXPA05008347A (uk)
MY (1) MY140723A (uk)
NO (1) NO20053626L (uk)
NZ (1) NZ541222A (uk)
PL (1) PL214680B1 (uk)
PT (1) PT1589976E (uk)
RU (2) RU2360681C2 (uk)
TW (1) TWI354556B (uk)
UA (1) UA80741C2 (uk)
WO (1) WO2004069260A1 (uk)
ZA (1) ZA200506221B (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
JP2008515810A (ja) * 2004-10-04 2008-05-15 ウェイン ステイト ユニヴァーシティ 子宮内膜腔および子宮に対する外科的処置の準備における子宮内膜菲薄化のためのアロマターゼ阻害剤の使用
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
WO1990010462A1 (en) * 1989-03-10 1990-09-20 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
TR200102867T2 (uk) 1998-06-11 2002-06-21 Endorecherchel@Inc
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CA2434611A1 (en) 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders
WO2002074315A1 (de) 2001-03-21 2002-09-26 Schering Aktiengesellschaft Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
WO2003039455A2 (en) 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
CA2472240A1 (en) 2002-01-22 2003-07-31 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
WO2003082299A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Improved hormone replacement therapy
WO2003082336A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Female birth control method
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1578930A4 (en) * 2002-06-27 2008-07-02 Centocor Inc CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
AR043013A1 (es) 2005-07-13
AU2004210184A1 (en) 2004-08-19
RU2008138166A (ru) 2010-03-27
EP1589976B1 (en) 2007-10-03
RU2005127667A (ru) 2006-03-27
TW200503731A (en) 2005-02-01
US20110009373A1 (en) 2011-01-13
PL377939A1 (pl) 2006-02-20
RU2360681C2 (ru) 2009-07-10
HK1082918A1 (en) 2006-06-23
PL214680B1 (pl) 2013-09-30
CN1747736A (zh) 2006-03-15
IS2547B (is) 2009-10-15
US20060142256A1 (en) 2006-06-29
KR20050098296A (ko) 2005-10-11
MXPA05008347A (es) 2005-11-04
TWI354556B (en) 2011-12-21
NZ541222A (en) 2008-12-24
GB0302572D0 (en) 2003-03-12
CN100393360C (zh) 2008-06-11
CO5580789A2 (es) 2005-11-30
IS8008A (is) 2005-08-30
EP1589976A1 (en) 2005-11-02
CA2513910C (en) 2012-04-03
EP1857111A2 (en) 2007-11-21
ES2293215T3 (es) 2008-03-16
WO2004069260A1 (en) 2004-08-19
US7910570B2 (en) 2011-03-22
KR101075929B1 (ko) 2011-10-26
IL169583A0 (en) 2007-07-04
ATE374612T1 (de) 2007-10-15
ZA200506221B (en) 2006-05-31
BRPI0407039A (pt) 2006-01-17
JP2006516602A (ja) 2006-07-06
AU2004210184B2 (en) 2007-01-04
DE602004009288T2 (de) 2008-07-10
EP1857111A3 (en) 2009-03-04
DE602004009288D1 (de) 2007-11-15
JP4658918B2 (ja) 2011-03-23
CA2513910A1 (en) 2004-08-19
PT1589976E (pt) 2007-11-22
UA80741C2 (en) 2007-10-25
JP2011001388A (ja) 2011-01-06
MY140723A (en) 2010-01-15
CY1107816T1 (el) 2013-06-19
NO20053626L (no) 2005-08-26

Similar Documents

Publication Publication Date Title
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
HK1082918A1 (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
NO20054133D0 (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
NL1026490A1 (nl) Instructiesetextensie onder gebruikmaking van 3-byte escape opcode.
DE50307239D1 (de) Ausschleuseinrichtung
DE60311032D1 (de) Wandlervorrichtung
DK1755743T3 (da) Beta-hydroxybutyrat og derivater til behandling af depression og angst
NO20025188D0 (no) Anordning ved elektroniske apparater og utstyr
DE60336868D1 (de) Zeicheneingabevorrichtung
DK1623711T3 (da) Eksternt plaster indeholdende östrogen og/eller progestogen
DK1457208T3 (da) Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer
DK1322336T3 (da) Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder
DK1404148T3 (da) Indretning og fremgangsmåde til styring af tilbagekobling
DK1509990T3 (da) Konfiguration og fremgangsmåde til beskyttelse af omformerorganer
DE60207518D1 (de) Dämpfungseinrichtung
DK1626736T3 (da) C1-inhibitor med kort halveringstid til midlertidig behandling
DE50304827D1 (de) Gaserzeugungsvorrichtung
DE50308833D1 (de) Eingabevorrichtung
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
DE60321641D1 (de) Photopolymerisierbare Initiatorkombination und photopolymerisierbare Zusammensetzung
DK1638617T3 (da) Efterudladningsplasmasterilisationsindretning
DE60124078D1 (de) Photopolymerisierbare Initiatorkombination
DE602004018921D1 (de) D dienogest
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze